Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$983.80 USD
-10.15 (-1.02%)
Updated May 22, 2024 03:59 PM ET
After-Market: $984.18 +0.38 (0.04%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Regeneron Pharmaceuticals, Inc. [REGN]
Reports for Purchase
Showing records 81 - 100 ( 591 total )
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for REGN.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for REGN.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Novel Compounds to Treat ATTR Amyloidosis Appear on Track to Generate Peak Annual Revenues of $50B-Plus
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for REGN.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for REGN.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Sanofi Immunology Investor Event Highlights Dupixent Successes; COPD Readout in 2023; Making Inroads into China and More
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for REGN.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Eylea Rival List Narrows; Wet AMD Contender, KSI-301 Fails in a Phase 2b/3 Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for REGN.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Dupixent Trial For Omalizumab Refractory CSU Stopped Due to Futility
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Reassuring CANDELA Phase 2 Trial Data Turns Up the Heat in Battle for the Crown in Wet AMD; Reiterate Buy and $843 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for REGN.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Reports 4Q and FY 2021; The Triumvirate Strikes Again With Stellar Top-Bottom Beat
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Our Outlook for Regenerons Upcoming 4Q 2021 Earnings Report
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M